Polymorphisms at the APOA1/C3/A4 gene cluster and the APOE gene have been extensively studied in order to examine their potential association with plasma lipid levels, coronary heart disease risk and more recently with inter-individual variability in response to dietary therapies. Although the results have not been uniform across studies, the current research supports the concept that variation at these genes explains a significant, but still rather small, proportion of the variability in fasting and postprandial plasma lipid responses to dietary interventions. This information constitutes the initial frame to develop panels of genetic markers that could be used to predict individual responsiveness to dietary therapy for the prevention of coronary heart disease. Future progress in this complex area will come from experiments carried out using animal models, and from carefully controlled dietary protocols in humans that should include the assessment of several other candidate gene loci coding for products that play a relevant role in lipoprotein metabolism (i.e. APOB, CETP, LPL, FABP2, SRBI, ABC1 and CYP7).
Introduction
To reduce low-density lipoprotein cholesterol (LDLC), a major risk factor for coronary artery disease (CAD), the National Cholesterol Education Program (NCEP) Expert Panel recommends for the general population a diet providing Ͻ30 % of energy from fat, Ͻ10 % of energy from saturated (SAT) fat and Ͻ300 mg/d of cholesterol (NCEP Step 1). For subjects who are still hypercholesterolaemic on this diet, the Expert Panel recommends further restriction of saturated fat to Ͻ7 % of calories and cholesterol to Ͻ200 mg/d (NCEP Step 2) prior to use of drug therapy. Candidates for drug therapy after dietary treatment are those with LDLC values at or above 190 mg/dl, 160 mg/dl in the presence of two or more risk factors, or 130 mg/dl in the presence of coronary heart disease (CHD), with the goal of therapy being 30 mg/dl lower than the above values in each category.
The magnitude of plasma lipid responses to hypolipidaemic diet and drug therapies varies considerably among individuals (Ordovas, 1999; Ordovas & Schaefer, 1999a,b) . These differences may be due to interactions among multiple genetic and environmental factors that affect the absorption of dietary fat or cholesterol, the bioavailability of drugs, or the regulation of the multiple metabolic pathways involved in lipoprotein synthesis and catabolism. During the past two decades numerous studies have examined gene-diet and gene-drug interactions in the response of plasma lipid concentrations to changes in dietary fat and cholesterol (Tall et al. 1997) or to different pharmacological therapies (Carmena et al. 1993; Nemeth et al. 1995; Ordovas et al. 1995; Nestel et al. 1997) . In this paper we present the current knowledge regarding the association between alleles at the APOA1/C3/A4 gene cluster on chromosome 11 and the APOE locus on chromosome 19, the most broadly studied candidate gene loci involved on individual variability in dietary response.
Apolipoprotein A-I (APOA1)
ApoA-I is the major protein of HDL, an in vivo activator of the enzyme lecithin : cholesterol acyl transferase (LCAT) (Fielding et al. 1972) , and constitutes a key component of the reverse cholesterol transport process (Reichl & Miller, 1989) . The gene for apoA-I (APOA1) is clustered with the APOC3 and APOA4 genes on the long arm of human chromosome 11 (Bruns et al. 1984; Karathanasis, 1985) . This DNA region has been extensively analysed, resulting in the identification of several restriction fragment length polymorphisms (RFLPS). A number of studies have shown associations between some of these RFLPs and lipid abnormalities as well as increased CHD risk (Ordovas et al. 1991; Paul-Hayase et al. 1992; Tybjaerg-Hansen et al. 1993) , but other studies have failed to do so (Marshall et al. 1994) . Several rare genetic abnormalities at this locus have been associated with severe HDL deficiency and some of them with premature coronary atherosclerosis (Ordovas et al. 1989) .
A common variant due to adenine (A) to guanine (G) transition (G/A) has been described 75 bp upstream from the apoA-I gene transcription start site. Several studies have reported that individuals with the A allele, which occurs at a frequency of 0⋅15-0⋅20 in Caucasian populations, have higher levels of HDL-C and/or apoA-I than those subjects homozygous for the most common G allele (Juo et al. 1999; Ordovas, 1999) . The magnitude of the effects and the gender-diet interactions reported have differed among studies. A recent meta-analysis has examined the associations of the − 75 G/A polymorphism with plasma lipid profiles (Juo et al. 1999) . This analysis concluded that there may be a mild association with apoA-I levels and that this is more apparent in men than in women. The associations between this polymorphism and response to diet are summarized in Table 1 . Our own data (LopezMiranda et al. 1994a; Mata et al. 1998) (Table 1 ) support the notion that in well controlled dietary studies performed in normolipidaemic subjects, the A allele of this G/A polymorphism appears to be associated with hyper response to changes in the amount and saturation of dietary fat.
It is not clear whether the putative effect of this variant on HDL-C levels is due to the G to A substitution per se, or to linkage disequilibrium between the A locus and a distinct and as-yet-unidentified effector locus. In vitro analysis of the effects of this polymorphism on transcription has also yielded conflicting results. Smith et al. (1992) reported that the A allele decreased in vitro transcription by 30 %, consistent with their own in vivo turnover studies that showed decreased apoA-I synthetic rates in individuals with the A allele, although plasma HDL-C did not differ between GG and GA individuals. Tuteja et al. (1992) and Wang et al. (1998) reported that substitution of A for G decreased transcription about twofold, and Jeenah et al. (1990) reported a fourfold increase in transcription. Angotti et al. (1994) reported a five-to sevenfold increase in transcription associated to the A allele, and demonstrated that this may be due to reduced binding affinity of a nuclear factor to the A allele that results in increased transcription efficiency of the apoA-I promoter. More recently, Danek et al. (1998) have failed to find any direct effect of this polymorphism on transcriptional efficiency.
In summary, the mechanisms responsible for the observed effect are still unknown. This mutation may have a direct effect on liver and/or intestinal apoA-I gene expression, as suggested in previous studies, or it may be in linkage disequilibrium with a functional mutation in either of the neighbouring genes (APOC3 and APOA4). Further studies are needed to demonstrate these hypotheses.
Apolipoprotein C-III (APOC3)
ApoC-III is a component of chylomicrons, VLDL and HDL that is synthesized primarily in the liver and to a lesser extent in the intestine. In vitro, apoC-III inhibits LPL and also inhibits the binding of apoE-containing lipoproteins to the LDL receptor, but not to the LRP receptor. Several DNA polymorphisms have been reported in the APOC3 promoter region. These mutations are in linkage disequilibrium with the SstI site in the 3Ј untranslated region (C3238G) (Dammerman et al. 1993 ). Preliminary results have mapped an insulin-response element to a 42 nt fragment located between − 490 and − 449 relative to the transcription start site, and in vitro studies have demonstrated that transcriptional activity of the APOC3 gene was down-regulated by insulin only in the construct bearing the wildtype promoter, but not in those constructs containing the C −482 T and T −455 C variants . The C3238G polymorphism distinguishes between two alleles, S1 and S2. The S2 allele has been associated with elevated triacylglycerol, cholesterol, apoC-III concentrations, high blood pressure and increased CAD risk. The linkage disequilibrium between this mutation and those at the 5Ј region provide some suggestions toward understanding the molecular basis behind the increased levels of apoC-III found in subjects carrying the S2 allele and its association with hypertriglyceridaemia, and also suggest an active role of dietary fat in determining the effects associated with this polymorphism (Lopez-Miranda et al. 1997) . Several studies have examined the potential associations between some of the APOC3 polymorphisms and variability in plasma lipid response. The results are summarized in Table 1 . Overall, these data suggest that the APOC3 gene locus is involved in dietary response for both fasting and postprandial parameters.
Apolipoprotein A-IV (APOA4)
ApoA-IV is synthesized primarily in the intestine. Although its physiological role has not been established with certainty, several lines of evidence involve this apolipoprotein in several key steps of lipoprotein synthesis and catabolism. ApoA-IV plays a significant role in dietary fat absorption and chylomicron synthesis (Ordovas et al. 1989) Moreover, in vitro studies have shown that the activation of lipoprotein lipase (LPL) by apoC-II is mediated by apoA-IV, and that apoA-IV can serve as an activator of lecithin : cholesterol acyl transferase (LCAT). ApoA-IV-containing lipoproteins promote cholesterol efflux from cultured fibroblasts and adipose cells in vitro, and some evidence shows that apoA-IV may be one of the ligands for the HDL receptor.
Several genetically determined isoforms of apoA-IV have been detected, with those at amino acid positions 360 and 347 of the mature protein being the most common. The apoA-IV*2 isoform, characterized by the presence of His at position 360, instead of the common Gln that characterize the apoA-IV*1 allele, has an allele frequency for Caucasians in the range of 0⋅05 to 0⋅12. In some population studies the apoA-IV*2 allele has been associated with higher levels of HDLC and/or lower TG levels, but no associations have been observed in others. The common mutation (Thr 347 Ser) documented within subjects with the apoA-IV*1 isoform has been less studied in terms of lipid associations in populations; however several studies have implicated this isoform with individual variability of plasma lipid levels in response to diet intervention. His. The mechanisms by which these mutations may exert the observed effects are still unknown. The apoA-IV*2 allele binds to lipoproteins with higher affinity than apoA-IV*1 which may result in delayed hepatic clearance of chylomicron remnants as shown in metabolic studies. The substitution of Ser for Thr at position 347 induces changes in the secondary structure and a slight increase in hydrophilic profile at this position, which could result in a decrease in its affinity for lipids on the TRL particles. This could facilitate the exchange with apoC-II, thereby increasing LPL activity over those particles, which would in turn accelerate clearance of remnants. The increased influx of dietary cholesterol would down-regulate the LDL receptors with consequent increases in LDLC concentrations. Therefore, consumption of fat-rich diets would produce a greater increase in LDLC in Ser347 carriers.
Apolipoprotein E (APOE)
The APOE gene has been the locus more intensively examined in terms of its potential as a determinant of the individual variability in LDL-C response to diet interventions. This interest is obvious considering the pivotal role of apoE in lipoprotein metabolism.
ApoE in serum is associated with chylomicrons, VLDL and HDL, and serves as a ligand for the LDL receptor and the LRP (Beisiegel et al. 1989; Mahley, 1988) . When apoE deficiency is present, there is marked accumulation of cholesterol-enriched lipoproteins of density Ͻ1⋅006 g/ml containing apoB-48 and apoA-IV, as well as apoB-100 (Schaefer et al. 1986 ). Moreover, in this disorder there is delayed clearance of both apoB-100 and apoB-48 within TRL. The current data support the concept that apoE is important for the clearance of TRL and apoE containing HDL particles.
Genetic variation at the apoE locus results from three common alleles in the population, E*4, E*3 and E*2, with frequencies in Caucasian populations of approximately 0⋅15, 0⋅77 and 0⋅08, respectively (Davignon et al. 1988) . Population studies have shown that plasma cholesterol, LDL cholesterol and apoB levels are highest in subjects carrying the apoE4 isoform, intermediate in those with the apoE3 isoform, and lowest in those with the apoE2 isoform (Ordovas et al. 1987; Schaefer et al. 1994) . ApoE allelic variation may account for up to 7 % of the variation in total and LDL-C levels in the population (Davignon et al. 1988) . The association of the apoE4 isoform with elevated serum cholesterol levels is greater in populations consuming diets rich in saturated fat and cholesterol than in other populations. These epidemiological data indicate that the higher LDL cholesterol levels observed in subjects carrying the apoE4 isoform are manifested primarily in the presence of an atherogenic diet characteristic of certain societies, and that the response to dietary saturated fat and cholesterol may differ among individuals carrying different apoE alleles.
Previous findings related to this locus have been extensively reviewed (Ordovas, 1999; Ordovas & Schaefer, 1999a,b) and those findings are summarized in this work (Table 2) . It should be noted that despite the large number of studies examining the relation between APOE genetic variability and LDLC response to diet intervention, there is considerable inconsistency regarding the magnitude and significance of the reported associations, and this locus continues to be the subject of intense research.
Overall, a significant diet by apoE gene interaction was reported in studies with men alone. In those studies including men and women, significant effects were noted only in men, suggesting a significant gene-sex interaction. Another difference between the negative studies and those reporting significant apoE gene-diet interactions related to the baseline lipid levels of the subjects. Frequently, those studies reporting significant associations included subjects who were moderately hypercholesterolaemic and/or had significant differences in base TC and LDLC among the apoE genotype groups, suggesting that the significant gene × diet interaction is apparent only in subjects who are susceptible to hypercholesterolaemia. Concerning differences in dietary interventions, significant interactions were more commonly observed among studies in which total dietary fat and cholesterol were modified. It is possible that dietary cholesterol may play a significant effect in gene-dietary fat interaction.
Several mechanisms have been proposed to explain these apoE-related differences in individual response to dietary therapy. Some studies have shown that intestinal cholesterol absorption is related to apolipoprotein E phenotype, with apoE4 carriers absorbing more cholesterol than non-apoE4 carriers. Other mechanisms, such as different distribution of apoE on the lipoprotein fractions, LDL apoB production, bile acid and cholesterol synthesis, and postprandial lipoprotein clearance, may also be involved.
Conclusions
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